Effect of vitamin K2 ( MK-7 ) in treatment of diabetes

Phase 3

Recruiting

• Conditions: Diabetes.; Type 2 diabetes mellitus

• Registration Number: IRCT20190824044592N1
• Lead Sponsor: Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 68

Inclusion Criteria

Patients who have diabetes since 1 year ago
Glycated hemoglobin between 6.5 and 10 %
Not intake of Warfarin, Phenytoin, Phenobarbital, Dicoumarol, Phenprocoumon drugs
Patients treating with oral lowering blood glucose medications

Exclusion Criteria

Insulin injection
Have chronic diseases such as heart, liver, kidney, cancer disease
Having allergy to vitamin K
Pregnancy or lactation

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Glycated hemoglobin A1c. Timepoint: Glycated hemoglobin A1c will be measured at the beginning of the study and after 90 days of starting supplementation. Method of measurement: Enzymatic colorimetric method.;Fasting Plasma Insulin. Timepoint: Fasting Plasma Insulin will be measured at the beginning of the study (before the intervention) and after 90 days of starting supplementation . Method of measurement: Enzyme-linked immunosorbent assay.;Fasting Plasma Glucose. Timepoint: Fasting Plasma Glucose will be measured at the beginning of the study (before the intervention) and after 90 days of starting supplementation. Method of measurement: Enzymatic colorimetric method.;Insulin resistance indexes. Timepoint: Insulin resistance indexes will be calculated at the beginning of the study (before the intervention) and after 90 days of starting supplementation . Method of measurement: Calculation.

Secondary Outcome Measures

Name	Time	Method
Serum Triglycerides. Timepoint: At the beginning and exactly at the end of intervention ( 90 days later ). Method of measurement: Enzymatic colorimetric method.;Serum cholesterol. Timepoint: At the beginning and exactly at the end of intervention ( 90 days later ). Method of measurement: Enzymatic colorimetric method.;High-density lipoprotein. Timepoint: At the beginning and exactly at the end of intervention ( 90 days later ). Method of measurement: Enzymatic colorimetric method.;Low-density lipoprotein. Timepoint: At the beginning and exactly at the end of intervention ( 90 days later ). Method of measurement: Enzymatic colorimetric method.